Charles Schwab Investment Management Inc Aerie Pharmaceuticals Inc Transaction History

Charles Schwab Investment Management Inc

$515 Billion
Q3 2024

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$6.37 - $15.23 $46,341 - $110,798	7,275 Added 2.09%	355,296 $5.38 Million
Q2 2022 Aug 15, 2022	BUY	$4.95 - $9.16 $36,144 - $66,886	7,302 Added 2.14%	348,021 $2.61 Million
Q1 2022 May 13, 2022	BUY	$5.64 - $9.8 $88,756 - $154,222	15,737 Added 4.84%	340,719 $3.1 Million
Q4 2021 Feb 11, 2022	BUY	$7.02 - $13.33 $193,730 - $367,868	27,597 Added 9.28%	324,982 $2.28 Million
Q3 2021 Nov 16, 2021	SELL	$11.32 - $16.63 $206,782 - $303,780	-18,267 Reduced 5.79%	297,385 $3.39 Million
Q2 2021 Aug 16, 2021	BUY	$15.16 - $18.97 $255,461 - $319,663	16,851 Added 5.64%	315,652 $5.05 Million
Q1 2021 May 17, 2021	BUY	$13.12 - $20.9 $182,958 - $291,450	13,945 Added 4.9%	298,801 $5.34 Million
Q4 2020 Feb 16, 2021	BUY	$9.12 - $14.49 $25,235 - $40,093	2,767 Added 0.98%	284,856 $3.85 Million
Q3 2020 Nov 13, 2020	BUY	$10.46 - $14.46 $164,284 - $227,108	15,706 Added 5.9%	282,089 $3.32 Million
Q2 2020 Aug 14, 2020	BUY	$12.0 - $16.13 $32,376 - $43,518	2,698 Added 1.02%	266,383 $3.93 Million
Q1 2020 May 15, 2020	BUY	$11.84 - $25.52 $62,645 - $135,026	5,291 Added 2.05%	263,685 $3.56 Million
Q4 2019 Feb 07, 2020	BUY	$17.72 - $25.1 $137,347 - $194,550	7,751 Added 3.09%	258,394 $6.25 Million
Q3 2019 Nov 08, 2019	BUY	$18.41 - $28.0 $289,589 - $440,440	15,730 Added 6.7%	250,643 $4.82 Million
Q2 2019 Aug 09, 2019	BUY	$28.97 - $48.21 $482,871 - $803,564	16,668 Added 7.64%	234,913 $6.94 Million
Q1 2019 May 14, 2019	BUY	$36.32 - $49.25 $448,878 - $608,680	12,359 Added 6.0%	218,245 $10.4 Million
Q4 2018 Feb 14, 2019	SELL	$33.0 - $60.04 $43,791 - $79,673	-1,327 Reduced 0.64%	205,886 $7.43 Million
Q3 2018 Nov 13, 2018	BUY	$56.15 - $73.9 $424,157 - $558,240	7,554 Added 3.78%	207,213 $12.8 Million
Q2 2018 Aug 08, 2018	BUY	$47.85 - $70.45 $828,474 - $1.22 Million	17,314 Added 9.5%	199,659 $13.5 Million
Q1 2018 May 07, 2018	BUY	$51.15 - $61.0 $907,401 - $1.08 Million	17,740 Added 10.78%	182,345 $9.89 Million
Q4 2017 Jan 17, 2018	BUY	$50.85 - $65.1 $606,996 - $777,098	11,937 Added 7.82%	164,605 $9.84 Million
Q3 2017 Nov 13, 2017	BUY	$48.6 - $60.1 $7.42 Million - $9.18 Million	152,668	152,668 $7.42 Million

Others Institutions Holding AERI

# of Institutions

Shares Held

2.4M

Call Options Held

Put Options Held

View Full List

About AERIE PHARMACEUTICALS INC

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

More about AERI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account